Yahoo · Nov 14, 2026
AJOVY® Formally Included in China's National Reimbursement Drug List 2026
On November 14, NeuroGen announced that it's in-licensed innovative drug AJOVY® (fremanezumab injection) from TEVA has been successfully listed on China's National Reimbursement Drug List (NRDL) following the latest round of national price negotiations1. Marking a breakthrough as the first CGRP inhibitor covered by national insurance, AJOVY® achieved same-year NRDL inclusion after its initial approval in June—a milestone expected to dramatically improve patient access and relieve the long-term f

